Lysophosphatidic acid receptor 1 (LPA(1)) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia

BACKGROUND: Lysophosphatidic acid receptor 1 (LPA(1)) is in the spotlight because its synthetic antagonist has been under clinical trials for lung fibrosis and psoriasis. Targeting LPA(1) might also be a therapeutic strategy for cerebral ischemia because LPA(1) triggers microglial activation, a core...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaire, Bhakta Prasad, Sapkota, Arjun, Song, Mi-Ryoung, Choi, Ji Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701099/
https://www.ncbi.nlm.nih.gov/pubmed/31429777
http://dx.doi.org/10.1186/s12974-019-1555-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701099/
https://www.ncbi.nlm.nih.gov/pubmed/31429777
http://dx.doi.org/10.1186/s12974-019-1555-8

Ejemplares similares